AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative

• Published in: Case reports in medicine Vol. 2014; no. 2014; pp. 1 - 4
• Main Authors: Kline-Rogers, Eva, Froehlich, James B., Haymart, Brian, Heidt, Steven T., Puroll, Eric, Barnes, Geoffrey D.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01-01-2014; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Anticoagulants; Care and treatment; Case Report; Case studies; Complications and side effects; Diagnosis; Dietary supplements; Dosage and administration; Hemorrhage; Macular degeneration; Quality management; Risk factors; Vitamin E; Warfarin; United States
• ISSN: 1687-9627; 1687-9635
• DOI: 10.1155/2014/754147

Importance. The anticoagulant warfarin has been shown to interact with other medications, vitamin K containing foods, and over-the-counter products. These interactions may inhibit or potentiate the effect of warfarin, resulting in serious clotting or bleeding events. Observations. We report the case of an 84-year-old woman with atrial fibrillation, prescribed warfarin in May 2010 for stroke prevention. Her international normalized ratio (INR) was stable until April 2013, when she was prescribed AREDS (Age Related Eye Disease Study) formula pills, an eye vitamin compound, to slow the progression of age-related macular degeneration. This change was not reported to the Anticoagulation Service. Eighteen days later, she presented to the ED with groin and back pain and an INR of 10.4. An abdominal CT revealed a retroperitoneal hemorrhage with extension in multiple muscles. Both warfarin and AREDS were discontinued and the patient was discharged to subacute rehabilitation. This case was reviewed by the Anticoagulation Service and actions were taken to prevent similar adverse events. Conclusions. This report provides an example of the potential danger of supplement use, in this case, AREDS formula, in patients prescribed warfarin, and the importance of communicating medication changes to the providers responsible for warfarin management.